182 related articles for article (PubMed ID: 20132579)
21. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
[TBL] [Abstract][Full Text] [Related]
22. Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database.
Sidorenkov G; Voorham J; de Zeeuw D; Haaijer-Ruskamp FM; Denig P
BMJ Qual Saf; 2013 Apr; 22(4):339-47. PubMed ID: 23386729
[TBL] [Abstract][Full Text] [Related]
23. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
[TBL] [Abstract][Full Text] [Related]
24. Variation in the achievement of HbA
Bakke Å; Dalen I; Thue G; Cooper J; Skeie S; Berg TJ; Jenum AK; Claudi T; Fjeld Løvaas K; Sandberg S
Diabet Med; 2020 Sep; 37(9):1471-1481. PubMed ID: 31651045
[TBL] [Abstract][Full Text] [Related]
25. Quality of diabetes care among patients managed by teleconsultation.
Nikkanen T; Timonen M; Ylitalo K; Timonen O; Keinänen-Kiukaanniemi S; Rajala U
J Telemed Telecare; 2008; 14(6):295-9. PubMed ID: 18776074
[TBL] [Abstract][Full Text] [Related]
26. All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A(1c), systolic blood pressure, and low-density lipoprotein cholesterol levels.
Chiang HH; Tseng FY; Wang CY; Chen CL; Chen YC; See TT; Chen HF
PLoS One; 2014; 9(10):e109501. PubMed ID: 25347712
[TBL] [Abstract][Full Text] [Related]
27. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
Davis TM; Cull CA; Holman RR;
Diabetes Care; 2001 Jul; 24(7):1167-74. PubMed ID: 11423497
[TBL] [Abstract][Full Text] [Related]
28. Baseline treatments and metabolic control of 288,913 type 2 diabetes patients in a 10-year retrospective cohort in Malaysia.
Wan KS; Mustapha F; Chandran A; Ganapathy SS; Zakariah N; Ramasamy S; Subbarao GR; Mohd Yusoff MF
Sci Rep; 2023 Oct; 13(1):17338. PubMed ID: 37833402
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous control of intermediate diabetes outcomes among Veterans Affairs primary care patients.
Jackson GL; Edelman D; Weinberger M
J Gen Intern Med; 2006 Oct; 21(10):1050-6. PubMed ID: 16970554
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous control of blood glucose, blood pressure, and lipid among drug-treated Type 2 diabetes patients from Shaanxi province, North-Western China: A multicenter study.
Xu S; Sun F; Xu W; Jiao K; Shi B; Xie X; Wang Y; Zhu M; Ji Q
Niger J Clin Pract; 2016; 19(6):784-792. PubMed ID: 27811452
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of an mHealth-enabled hierarchical diabetes management intervention in primary care in China (ROADMAP): A cluster randomized trial.
Jia W; Zhang P; Zhu D; Duolikun N; Li H; Bao Y; Li X;
PLoS Med; 2021 Sep; 18(9):e1003754. PubMed ID: 34547030
[TBL] [Abstract][Full Text] [Related]
32. [Inertia and treatment compliance in patients with type 2 diabetes in primary care].
López-Simarro F; Brotons C; Moral I; Cols-Sagarra C; Selva A; Aguado-Jodar A; Miravet-Jiménez S
Med Clin (Barc); 2012 Apr; 138(9):377-84. PubMed ID: 22036458
[TBL] [Abstract][Full Text] [Related]
33. Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries.
Hermans MP; Brotons C; Elisaf M; Michel G; Muls E; Nobels F;
Eur J Prev Cardiol; 2013 Dec; 20(6):1095-105. PubMed ID: 22605788
[TBL] [Abstract][Full Text] [Related]
34. Type 1 diabetes management: Room for improvement.
Varkevisser RDM; Birnie E; Mul D; van Dijk PR; Aanstoot HJ; Wolffenbuttel BHR; van der Klauw MM
J Diabetes; 2023 Mar; 15(3):255-263. PubMed ID: 36808864
[TBL] [Abstract][Full Text] [Related]
35. Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes.
González-Clemente JM;
Eur J Clin Invest; 2008 Mar; 38(3):174-9. PubMed ID: 18257780
[TBL] [Abstract][Full Text] [Related]
36. Glycaemic, blood pressure and cholesterol control in 25 629 diabetics.
Pinchevsky Y; Butkow N; Chirwa T; Raal FJ
Cardiovasc J Afr; 2015; 26(4):188-92. PubMed ID: 26407221
[TBL] [Abstract][Full Text] [Related]
37. The Microalbuminuria Education Medication and Optimisation (MEMO) study: 4 years follow-up of multifactorial intervention in high-risk individuals with type 2 diabetes.
Crasto W; Morrison AE; Gray LJ; John E; Jarvis J; Brela J; Khunti K; Troughton J; Lawrence IG; McNally PG; Davies MJ
Diabet Med; 2020 Feb; 37(2):286-297. PubMed ID: 31505051
[TBL] [Abstract][Full Text] [Related]
38. The Veterans Affairs Implantable Insulin Pump Study: effect on cardiovascular risk factors.
Duckworth WC; Saudek CD; Giobbie-Hurder A; Henderson WG; Henry RR; Kelley DE; Edelman SV; Zieve FJ; Adler RA; Anderson JW; Anderson RJ; Hamilton BP; Donner TW; Kirkman MS; Morgan NA
Diabetes Care; 1998 Oct; 21(10):1596-602. PubMed ID: 9773717
[TBL] [Abstract][Full Text] [Related]
39. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
